AG真人官方

Avalon GloboCare Corp. (Nasdaq: ALBT) filed a Form 8-K dated 28 Jul 2025 to disclose that its wholly-owned subsidiary, Q&A Distribution, LLC, has entered a distribution agreement with Saga Health Corporation for the KetoAir™ breathalyzer device. The filing is made under Item 7.01 (Reg FD) and includes the related press release as Exhibit 99.1.

No financial terms, volume commitments or revenue projections were provided. Management expressly states the information is furnished, not filed, thereby avoiding automatic incorporation into other SEC documents. While the agreement could broaden ALBT鈥檚 presence in the metabolic health diagnostics market, investors have insufficient data to quantify potential sales or profitability impact. No other material events, financial statements, or pro-forma data accompany this report.

Fusion Fuel Green PLC (HTOO) entered a July 22 2025 Securities Purchase Agreement to raise $4.3 million gross through a private placement of (i) 269,459 Class A ordinary shares, (ii) 541,706 pre-funded warrants (exercise $0.0035), (iii) 1,622,330 warrants at $4.926, and (iv) 811,165 warrants at $9.852. All warrants are immediately exercisable for three years and subject to a 4.99% (optionally 9.99%) beneficial-ownership cap.

Use of proceeds: mandatory full repayment of outstanding Senior Convertible Notes dated Jan 10 2025 and Mar 3 2025; any excess for working capital and fees. Company must file an SEC resale registration within 15 days and keep it effective while securities remain restricted.

Concurrently, the company executed Redemption Agreements cancelling the now-converted 2025 Notes (redemption price $0) and exchanging prior 2025 warrants for 294,658 new warrants expiring Jan 10 2028 / Mar 3 2028, also capped at 4.99% ownership. Note investors waived antidilution, participation and change-of-control rights, and accepted a "most-favored-nations" clause.

Key implications: cash infusion retires debt and removes restrictive note covenants, but authorizes up to ~3.5 million additional shares, creating dilution and warrant overhang. Transaction conducted under Section 4(a)(2)/Rule 506(b) exemptions.

PSQ Holdings, Inc. (PSQH) filed a Form 4 indicating that Chief Financial Officer and Director James Rinn received an equity award on 11-Jul-2025. The transaction involves 250,000 restricted stock units (RSUs) issued under the company鈥檚 2023 Stock Incentive Plan. Each RSU entitles the holder to one share of Class A common stock upon vesting. The award is structured to vest in three equal annual tranches beginning 1-Jun-2025 and continuing through 1-Jun-2027. The filing shows no cash consideration (exercise price $0), confirming the grant is part of compensation rather than a market purchase or sale. Following the grant, Rinn holds 250,000 derivative securities directly, with no changes reported in non-derivative share ownership. No additional insider transactions or amendments appear in the document.

Vor Biopharma Inc. (NASDAQ: VOR) 鈥� Schedule 13D/A Amendment No. 2 filed 9 July 2025

Venture investor 5AM Ventures and related entities disclosed that they reduced their collective beneficial ownership below the 5 % reporting threshold. Following open-market sales on 8 July 2025, the group now controls 4,422,863 common shares, equal to 3.5 % of VOR鈥檚 124,959,520 shares outstanding (per the issuer鈥檚 14 May 2025 10-Q).

Key transaction details: 5AM Ventures VI, L.P. sold 1,400,444 shares and 5AM Opportunities I, L.P. sold 538,416 shares, for a combined 1,938,860 shares at prices ranging from $2.40鈥�$3.00 (weighted-average $2.4568). After the sales, individual holdings are:

• 5AM Ventures VI, L.P.: 3,194,645 shares (2.6 %) 鈥� shared voting/dispositive power
• 5AM Opportunities I, L.P.: 1,228,218 shares (1.0 %) 鈥� shared voting/dispositive power
• Managing members Andrew J. Schwab & Dr. Kush Parmar share control over the full 4.42 M shares

Implications: The filing confirms that the venture group is no longer classified as an 鈥渋nsider鈥� under the 5 % threshold, potentially reducing governance influence. The sizable sale may create temporary supply pressure, but the funds retain a meaningful 3.5 % position, signalling continued (albeit reduced) exposure to VOR鈥檚 clinical pipeline.

Avalon GloboCare (Nasdaq: ALBT) filed an 8-K disclosing a definitive agreement dated June 23 2025 with subsidiary Q&A Distribution and Qi Diagnostics to co-develop a volatile-organic-compound breathalyzer for THC screening.

The four-stage project requires Q&A to fund up to $975,000 in milestone payments: $95k (stage 1), $180k (stage 2), $300k (stage 3) and $400k (stage 4).

In return, Q&A earns a passive financial interest in the resulting intellectual property, escalating from 6% after milestone 1 to 50% if all milestones are met; Qi Diagnostics retains operational control of the IP.

Either party may terminate on 30-days notice, but vested IP interests survive. No revenue projections, regulatory approvals or guidance were provided. Exhibits 10.1 and 99.1 contain the full agreement and press release.